Dr. Kimberly MacGregor Named 2017 Litvak Fellowship Recipient

Kimberly MacGregor named 2017 Litvak Fellowship Recipient


Dr. Kimberly MacGregor, a second-year postgraduate student in the Jonathan and Maxine Ferencz Advanced Education Program in Prosthodontics, is the 2017 recipient of the Dr. Harold Litvak Junior Fellowship in Prosthodontics. Each year, the Litvak Fellowship is awarded to the second-year postgraduate student in prosthodontics who has earned the highest academic standing.

"Dr. MacGregor is an exemplary student with demonstrated excellence in academics, patient care, and teaching. Her superb skills, approachability, and engaging smile will serve her well as she pursues a career in teaching and clinical practice," said Dr. Leila Jahangiri, clinical professor and chair of the Department of Prosthodontics. Dr. MacGregor holds a DDS degree from the Instituto Superior de Ciências da Saúde Egas Moniz in Portugal. She joined NYU Dentistry in 2013 as a student in the Program for International Dentists in Prosthodontics. Upon completion of that program, she was awarded a clinical assistant fellowship in prosthodontics, and subsequently entered the Jonathan and Maxine Ferencz Advanced Education Program in Prosthodontics.

Dr. MacGregor describes prosthodontics as "combining science and art to provide patient-centered care to those who present with congenital or acquired defects that require a multidisciplinary intervention. The Jonathan and Maxine Ferencz Advanced Education Program in Prosthodontics offers exceptional didactic, clinical, and research experiences that have provided me with profound knowledge of the field of prosthodontics," she says.

The Litvak Fellowship was established in 1999 through a generous grant from Mrs. Adele Block in honor of her dentist, Dr. Harold Litvak, an adjunct clinical professor of prosthodontics and a generous donor to the College. Mrs. Block is a member of the family that owned the Block Drug Company, Inc., a major producer of oral and general healthcare products, which is now a division of GlaxoSmithKline.